Gain detailed insights into the trading activity of Congress members for Crinetics Pharmaceuticals on our government trades page. Stay updated on how elected officials are investing in CRNX.

Crinetics Pharmaceuticals - Government Trades

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

QuantumScape QS Stock

Equities

Mid Cap

News

Movers

General

APGE

CRNX

JOBY

KYMR

LNTH

PLUG

SMMT

XPEV

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit Therapeutics, Plug Power and XPeng Inc.

XPeng &amp; QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

Nvidia stock

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ADSK

GTLB

NVDA

SRCL

UPST

Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday

xr:d:DAFjzSNzgvg:2,j:47806933381,t:23052405

Intraday Update

BNTX

CSIQ

CVAC

FLNC

FSLR

IGMS

LOAR

MRNA

NVAX

SPWR

VIPS

WOOF

Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday

Biotech

Health Care

Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically significant efficacy &amp; safety, with plans for FDA submission in 2024.

Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here&#39;s Why

Penny Stocks

Small Cap

ACMR

AFIB

ALHC

ALPN

AUGX

BTDR

BYND

CJET

CLSK

CMTL

COIN

DCGO

DRCT

ELVN

ENVB

FUSN

GWAV

HOTH

HUYA

JOAN

LICY

MARA

MBTC

MNPR

MSTR

NCMI

OTRK

PIXY

PRSO

PRTG

SEEL

SMCI

SOUN

SPIR

STNE

SWIN

VERB

WORX

ZCAR

ZEPP

Shares of  Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.

Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

DAVA

FUFU

MNTK

VALN

U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.

National CineMedia Reports Upbeat Results, Joins Nordstrom, Core &amp; Main And Other Big Stocks Moving Higher On Tuesday

ARVN

ARWR

CLDX

DELL

EVBG

MLTX

NTAP

OPRA

PTCT

RDNT

RGNX

RMBS

ROOT

RPAY

SANA

XPOF

YMAB

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) released initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound being developed for 

Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study

Short Ideas

NXGN

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Top 4 Health Care Stocks That Should Keep You Up At Night

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) shares are trading higher Tuesday.

What&#39;s Going On With Crinetics Pharmaceuticals Stock?

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals Inc

DURECT Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET&#xAE; line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P., a North-American focused private equity firm.
<a href="https://mma.prnewswire.com/media/81466/DURECT_LOGO_2023.html">www.durect.com</a>) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer." alt="DURECT Corporation (<a href="http://www.durect.com/">www.durect.com</a>) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer."&gt;
Under the terms of the agreement, LIC paid&nbsp;DURECT&nbsp;$17.5 million in exchange for certain assets and liabilities associated with&nbsp;the ALZET&nbsp;product line. Simultaneous with this transaction, DURECT has paid off all remaining obligations under the term loan agreement with Oxford Finance LLC.&nbsp;

Asset Sales

DRRX

DURECT Sells ALZET Osmotic Pumps for $17.5M, Pays Off Loan Obligations

TD Cowen analyst Kevin Kopelman downgrades Despegar.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) from Buy to Sell and raises the price target from $12 to $14.

Downgrades

DESP

TD Cowen Downgrades Despegar.com to Sell, Raises Price Target to $14

<a href="https://www.reuters.com/business/energy/trump-prepares-wide-ranging-energy-plan-boost-gas-exports-oil-drilling-sources-2024-11-25/" title="https://www.reuters.com/business/energy/trump-prepares-wide-ranging-energy-plan-boost-gas-exports-oil-drilling-sources-2024-11-25/">https://www.reuters.com/business/energy/trump-prepares-wide-ranging-energy-plan-boost-gas-exports-oil-drilling-sources-2024-11-25/</a>

Commodities

Reuters Reported President Elect Trump Plans To Repeal Biden's Clean Power Plan, Boost Natural Gas, Lift Pause On New LNG Export Permits, And Expedite Pending Approvals

Earnings

Super Hi International Q3 EPS $0.06 Misses $0.21 Estimate, Sales $198.62M Miss $227.49M Estimate

Tractors and Farm Equipment Limited, is the largest shareholder of AGCO with a 16.3% long-term strategic ownership interest in the Company.

AGCO

AGCO Shareholder TAFE Urges To Separate Board Chair And CEO Roles At 2025 Annual Meeting

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) investors have no shortage of reasons to continue bidding up NVDA stock. Primarily, the semiconductor stalwart — known for its advanced graphics processors that undergird artificial-intelligence-based platforms and applications — recently posted financial results for the third quarter that<a href="https://www.benzinga.com/24/11/42099904/nvidia-q3-earnings-highlights"> handily beat expectations</a>.
Management disclosed earnings per share of 81 cents, outpacing Wall Street's expectation calling for 75 cents. Notably, the tech firm beat its bottom-line target for eight straight quarters. On the top line, Nvidia rang up sales of $35.1 billion, up a whopping 94% on a year-over-year basis. This tally also exceeded the consensus view of $33.12 billion.
According to Wedbush Securities Managing Director Dan Ives, the chipmaker's results were a "jaw-dropper." Further, the market expert<a href="https://www.benzinga.com/markets/equities/24/11/42102642/nvidia-delivered-jaw-dropping-q3-earnings-says-dan-ives-this-is-the-fourth-revolution-playing-out-in-front-of-our-eyes"> emphasized the transformative potential</a> of the underlying AI innovation. "This is the fourth revolution playing out in front of our eyes," Ives told CNN.
Not to be left outdone, CNBC personality Jim Cramer<a href="https://www.benzinga.com/news/global/24/11/42129914/jim-cramer-doubles-down-on-nvidia-demand-is-accelerating-as-ai-customers-have-no-choice-but-to-buy-its-chips"> pounded the table</a> on NVDA stock. "The demand is accelerating because the payoff is so great," the analyst remarked, mentioning Nvidia CEO Jensen Huang's claim that customers earn five dollars for every dollar invested in Nvidia chips.
Still, not every indicator is so glaringly positive for NVDA stock. Interestingly, when the tech giant released its Q3 report last week, the initial response wasn't exactly encouraging. Instead,<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42107846/nvidia-slides-during-thursday-pre-market-despite-beating-q3-estimates-even-outstanding-isnt-enough-for-some-investors"> shares slipped</a> during the pre-market hours of the Nov. 21 session. As the company continues to bring home the goods, expectations also rise, possibly presenting challenges.
Conspicuously, on Friday, NVDA stock dropped more than 3%. During the session,<a href="https://fintel.io/sof/us/nvda"> options flow data</a> — which focuses exclusively on big block transactions likely placed by institutional or professional investors — saw a significant influx of transactions with apparently bearish implications: both long puts and short calls. This dynamic raises suspicions that some market participants are becoming skeptical about Nvidia.
The Direxion ETFs: For investors that enjoy approaching the equities arena from a tactical view, financial services provider Direxion offers two directionally opposite exchange-traded funds. Optimists in the AI narrative may consider Direxion Daily NVDA Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDU#NASDAQ">NVDU</a>), which seeks daily investment results of 200% of the performance of NVDA stock.
Those who are pessimistic about Nvidia's rally sustaining itself may consider Direxion Daily NVDA Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDD#NASDAQ">NVDD</a>). This ETF attempts to replicate 100% of the inverse performance of NVDA stock. To be clear, both leveraged and inverse ETFs are designed to be held for periods lasting no longer than one day. Exposure beyond this recommended period may lead to valuation erosion due to the daily compounding of leverage.
The NVDU ETF: Since the start of the year, the NVDU ETF returned traders just over 359%, highlighting the blistering results that Nvidia posted. Still, some kinks in the armor raise questions.
<ul>
<li>In the trailing month, NVDU gained just over 1%, potentially revealing investor hesitation regarding the overall AI message.</li>
<li>The leveraged bull fund is comfortably above its 200-day moving average. However, the price action is narrowing toward its 50 DMA, warranting vigilance.</li>
</ul>
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXeQdd2BM4qeTSFWYs3aQVUBd2kOe6jRoNa2rxAZ0VW7ro2wiFm2UkW30cZJozR7WbVJO8eSNwN5GRbu8-bm4oB-lFyiiHk0g0azkjggkwwjhYDMJ555D9xNW8eQbhggQgCIlw4_IQ?key=DULWMCTnciRpWBUBkeoLDsyd" alt="" /></figure>
The NVDD ETF: Unsurprisingly, the NVDD ETF struggled badly this year, losing almost 73% of value since the beginning of January. However, it's possible that sentiment may be reversing.
<ul>
<li>Friday's price action brought the inverse fund level with its 20-day exponential moving average. Nvidia pessimists now have the 50 DMA within realistic striking distance.</li>
<li>It's worth noting that NVDD enjoyed a dramatic surge in volume since the middle of November, potentially reflecting a shift in market appetite for AI.</li>
</ul>
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXc6n1RW4tEJZNtITFmqx3JCWlCotkhm0Y3Ode37mtzHwWoVjcNPSk84ZVkMaZnBv8lG4b_a_wY0rIAAIK573o9TUOPRzGuKjiwG9jhbeqOKBPUilcT-6N9hw4N2C5alSdDDyLehSA?key=DULWMCTnciRpWBUBkeoLDsyd" alt="" /></figure>
Featured image by <a href="https://pixabay.com/users/nanadua11-4908484/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=5268574">Nana Dua</a> from <a href="https://pixabay.com/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=5268574">Pixabay</a>.

Long Ideas

Technicals

ETFs

NVDD

NVDU

Raging AI Debate Delivers Fuel For Direxion's Nvidia-Focused Funds NVDU And NVDD

Santech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEC#NASDAQ">STEC</a>) ("Santech" or the "Company") announced today that it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on November 21, 2024 stating that, as a result of not having timely filed its annual report on Form 20-F for the year ended June 30, 2024, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. This notice has no immediate effect on the listing or trading of the Company's American depositary shares on the Nasdaq.
Under Nasdaq's listing rules, the Company has 60 calendar days to submit a plan to regain compliance. If the plan is accepted by Nasdaq, the Company can be granted up to 180 calendar days from the Form 20-F's due date, or until May 14, 2024, to regain compliance.
The Company is currently working with its advisers to prepare the Filing or to formulate the requisite plan to regain compliance and intends to submit such Filing or such plan to Nasdaq within the timeframe required under Nasdaq's Rules.

Government

Regulations

STEC

Santech Faces Nasdaq Non-Compliance Notice Over Delayed Filing Of Its Annual Report On Form 20-F For Year Ended June 30, 2024

Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) is ramping up efforts to challenge Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) in the artificial intelligence (AI) chip market, worth over $100 billion. 
From a bustling engineering lab in Austin, Texas, Amazon&#8217;s engineers are pushing to market its latest AI chip, Trainium 2, as quickly as possible, Bloomberg <a href="https://www.bloomberg.com/news/features/2024-11-24/amazon-plans-to-rival-nvidia-with-its-own-ai-chips?srnd=phx-technology&amp;sref=TBDibEcD" target="_blank" rel="noreferrer noopener">reports</a>. Rami Sinno spearheads the Trainium 2 project and leads Amazon&#8217;s chip design and testing.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25032053/newplot-12.png" alt="" class="wp-image-662826" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25032053/newplot-12.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25032053/newplot-12-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42146205/gaps-growth-drivers-market-share-gains-brand-momentum-and-raised-guidance-analysts-weigh-in" rel="noreferrer noopener">Gap&#8217;s Growth Drivers: Market Share Gains, Brand Momentum, And Raised Guidance – Analysts Weigh In</a>
Despite Nvidia&#8217;s significant lead in AI hardware, Amazon&#8217;s ambitions to reduce dependency on external suppliers and deliver competitive AI solutions have gained traction.
Amazon&#8217;s latest AI chip, Trainium 2, offers improved performance with four times the computational power and three times the memory of its predecessor, per the report.
Engineers have streamlined its design by reducing internal components and improving heat management. The chip is central to Amazon&#8217;s strategy of scaling its AI capabilities and offering a cost-effective alternative to Nvidia hardware.
Prominent AI startups, including Anthropic, are adopting Amazon&#8217;s Trainium chips for their workloads. Last week, Amazon <a target="_blank" href="https://www.benzinga.com/24/11/42141911/amazon-and-anthropic-deepen-4-billion-ai-partnership-with-claude-35-launch" rel="noreferrer noopener">increased its funding</a> in Anthropic to $8 billion, solidifying its collaboration on AI advancements and positioning Amazon Web Services (AWS) as the startup&#8217;s primary cloud provider.
In October, Amazon signed a five-year agreement with Databricks to deliver cost-efficient <a target="_blank" href="https://www.benzinga.com/news/24/10/41337034/amazon-strikes-at-nvidias-stronghold-through-databricks-deal-cutting-ai-costs-by-40" rel="noreferrer noopener">AI-building solutions</a> to businesses.
The collaboration focuses on Amazon&#8217;s Trainium AI chips, offering a budget-friendly alternative to Nvidia&#8217;s widely used GPUs for AI customization. Databricks intends to pass on the savings from Trainium&#8217;s use to customers, challenging Nvidia&#8217;s dominance in the AI hardware market.
Amazon faces hurdles in software development, an area where Nvidia excels. Its Neuron SDK, still in its early stages, must evolve to match the ease and flexibility Nvidia offers to AI developers.
Meanwhile, Nvidia&#8217;s Blackwell chips won&#8217;t <a target="_blank" href="https://www.benzinga.com/news/24/10/41405124/whats-going-on-with-nvidia-stock-on-friday" rel="noreferrer noopener">reach the market</a> until early 2025, impacting significant clients such as AWS. Production challenges at Nvidia have forced AWS to await bulk production of Blackwell chips for its data centers. AWS Chief Matt Garman highlighted the delay during an interview on Bloomberg Television, citing Nvidia&#8217;s production adjustments.
In September, DA Davidson&#8217;s Gil Luria downgraded Microsoft Corp to Neutral, <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40986921/microsofts-ai-lead-shrinks-analyst-downgrades-stock-as-amazon-and-google-close-the-" rel="noreferrer noopener">citing diminishing AI</a> and cloud leadership as key factors. Luria highlighted AWS and Alphabet Inc Google Cloud&#8217;s strides in silicon deployment, outpacing Microsoft&#8217;s Azure in data center advancements. Despite early AI gains, Luria flagged competitors like AWS and GitLab as catching up to GitHub Copilot, challenging Microsoft&#8217;s edge in innovation.
Price Action: AMZN stock closed lower by 0.64% at $197.12 on Friday.
Image via Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42144915/china-unveils-global-ai-governance-committee-with-alibaba-cloud-founder-at-the-helm" target="_blank" rel="noreferrer noopener">China Unveils Global AI Governance Committee With Alibaba Cloud Founder At The Helm</a></li>
</ul>

Media

AMZN

MSFT

Amazon's AI Chip Strategy Targets Nvidia's Dominance In Data Centers

BEDU

Bright Scholar Education Q4 Adj EPADS $(0.44) Up From $(0.52) YoY, Sales $50.53M Down From $77.12M YoY

Needham analyst Mike Matson reiterates LivaNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVN#NASDAQ">LIVN</a>) with a Buy and maintains $75 price target.

Reiteration

LIVN

Needham Reiterates Buy on LivaNova, Maintains $75 Price Target

Transaction is expected to add approximately $180 million to Vertical's balance sheet, including through the conversion of approximately $130 million of debt into equity, significantly reducing Vertical's debt. The conversion price of the remaining convertible notes will be fixed.
Stephen Fitzpatrick, retains a strategic role as a board director to guide the company through its Flightpath 2030 Strategy. &nbsp;

EVTL

Vertical Aerospace Secures Agreement Under Which Mudrick Capital Will Commit Up To $50M In The Next Equity Round

Exane BNP Paribas analyst Kevin Grundy initiates coverage on Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) with a Outperform rating and announces Price Target of $48.

Initiation

BF/B

Exane BNP Paribas Initiates Coverage On Brown-Forman with Outperform Rating, Announces Price Target of $48

<a href="https://www.wsj.com/articles/hong-kong-is-becoming-hub-for-financial-crime-u-s-lawmakers-say-39043e46" title="https://www.wsj.com/articles/hong-kong-is-becoming-hub-for-financial-crime-u-s-lawmakers-say-39043e46">https://www.wsj.com/articles/hong-kong-is-becoming-hub-for-financial-crime-u-s-lawmakers-say-39043e46</a>

Legal

Wall Street Journal Reports U.S. House Committee Leaders Urge Rethink Of Banking Ties With Hong Kong, Citing Money-Laundering And Sanctions Evasion

Shares of Uxin Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NYSE">UXIN</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/UXIN/earnings">second-quarter financial results.</a>
Uxin posted quarterly sales of $70.85 million, up from $48.80 million in the year-ago period
Uxin shares rose 3% to $6.50 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) gained 59.2% to $2.77 in pre-market trading after climbing around 18% on Friday.</li>
<li>Quantum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) rose 40.4% to $12.84 in pre-market trading after jumping 127% on Friday.</li>
<li>KULR Technology Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) gained 29.8% to $0.5777 in pre-market trading after gaining around 7% on Friday.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) gained 28.4% to $23.59 in pre-market trading after jumping around 69% on Friday.</li>
<li>Arqit Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) gained 22% to $15.76 in pre-market trading after gaining 21% on Friday.</li>
<li>NOVONIX Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVX#NASDAQ">NVX</a>) gained 19.1% to $2.31 in pre-market trading. Novonix secured a 32,000-tonne offtake agreement with Volkswagen&#8217;s PowerCo for synthetic graphite supply.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) gained 16.9% to $7.13 in pre-market trading after jumping 28% on Friday.  </li>
<li>Allot Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) climbed 16.7% to $4.94 in pre-market trading. Allot, last week, reported better-than-expected quarterly financial results.</li>
<li>Lionsgate Studios Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) gained 11.2% to $7.89 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Akoustis Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTS#NASDAQ">AKTS</a>) shares tumbled 37.5% to $0.0629 in pre-market trading</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) shares fell 17.8% to $0.1560 in pre-market trading. Aptose Biosciences shares dipped 22% on Friday after the company announced the pricing of an $8 million public offering.</li>
<li>X3 Holdings Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) declined 16.6% to $1.76 in pre-market trading.</li>
<li>NewGenIvf Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) fell 16.1% to $0.43 in pre-market trading after declining 6% on Friday.</li>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) fell 13.9% to $0.0173 in pre-market trading. Elevai Labs implemented a 1-for-200 reverse stock split to retain Nasdaq listing, reducing shares to 3.07 million.</li>
<li>Gold Resource Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GORO#NYSE">GORO</a>) shares fell 13.1% to $0.1368 in pre-market trading after gaining 6% on Friday.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) dipped 12.4% to $0.1063 in pre-market trading after falling over 4% on Friday.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) shares dipped 6.9% to $22.15 in pre-market trading. ZIM Integrated Shipping Services, last week, reported better-than-expected third-quarter financial results and raised its FY24 adjusted EBIT and EBITDA guidance.</li>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) fell 5.9% to $7.00 in pre-market trading.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) fell 4.3% to $6.90 in today's pre-market trading after jumping around 25% on Friday. Kingsoft Cloud, last week, reported a fiscal third-quarter 2024 revenue of 1.89 billion Chinese yuan ($268.7 million), up by 16.0% year-on-year, beating the analyst consensus estimate of $247.46 million</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Government Trades

Crinetics Pharmaceuticals Inc

top performing CRNX trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga